Variant position: 562 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 659 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LSRYVLDDEYTSSVGSKFPV RWSPPEVLMYSKFSSKSDIWA
Mouse LSRYVLDDEYTSSVGSKFPV RWSPPEVLMYSKFSSKSDIWA
Chicken LSRYVLDDEYTSSMGSKFPV RWSPPEVLLYSKFSSKSDVWS
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
2 – 659 Tyrosine-protein kinase BTK
402 – 655 Protein kinase
542 – 542 Inhibitor; via carbonyl oxygen
551 – 551 Phosphotyrosine; by LYN and SYK
551 – 551 Y -> F. Loss of phosphorylation of GTF2I.
561 – 563
Genomic organization of the Btk gene and exon scanning for mutations in patients with X-linked agammaglobulinemia.
Hagemann T.L.; Chen Y.; Rosen F.S.; Kwan S.-P.;
Hum. Mol. Genet. 3:1743-1749(1994)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS XLA SER-334; ARG-506; GLN-520; TRP-562 AND LYS-630;
Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase.
Conley M.E.; Fitch-Hilgenberg M.E.; Cleveland J.L.; Parolini O.; Rohrer J.;
Hum. Mol. Genet. 3:1751-1756(1994)
Cited for: VARIANTS XLA ASP-113; CYS-361; GLN-520; PRO-542; TRP-562; LYS-630 AND PRO-652;
DNA-based mutation analysis of Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinaemia.
Vorechovsky I.; Vihinen M.; de Saint Basile G.; Honsova S.; Hammarstroem L.; Mueller S.; Nilsson L.; Fischer A.; Smith C.I.E.;
Hum. Mol. Genet. 4:51-58(1995)
Cited for: VARIANTS XLA SER-25; TRP-288; MET-370; VAL-509; PRO-525; LYS-526; TRP-562; VAL-582 AND ARG-594;
Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course.
Holinski-Feder E.; Weiss M.; Brandau O.; Jedele K.B.; Nore B.; Baeckesjoe C.-M.; Vihinen M.; Hubbard S.R.; Belohradsky B.H.; Smith C.I.E.; Meindl A.;
Cited for: VARIANTS XLA GLU-19; HIS-28; ASN-61; PRO-117; HIS-127; ARG-155; PRO-295; PHE-369; GLY-372; ARG-414; TYR-506; GLY-521; GLN-525; SER-559; TRP-562; GLU-594; THR-619; GLY-626 AND HIS-641;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.